Cell therapy, bioprocessing, microbial, and other diverse programs across the biotechnology stack from biologics companies, to CROs/CMOs, to culture media and reagent companies. From startups pushing the edge to major manufacturers at large commercial scale.
Customers span cell academic research to large commercial ventures where we translate our platform into progress.
A representative slice of the work — one from each persona area. More detailed case studies are available on request, or via the technical one-pagers below.
The approach. Multi-omic characterization of published T cell and Treg expansion protocols. VHL identified stress response signatures in standard media and mapped ~50 key nutrients expected to improve viability and expansion.
The approach. Multi-omic characterization of the cell line in production conditions. VHL identified specific metabolic bottlenecks limiting productivity and delivered a fully chemically defined HEK basal media formulation — designed to be transparent, cheaper, and hold critical quality attributes stable.
The approach. Multi-omic profiling of the E. coli production strain in traditional LB culture media. VHL delivered a custom media supplement of 22 new and additional ingredients — mechanism-backed redesign, not empirical screening.
The approach. Deep characterization across multiple cell type systems — pushing platform generality beyond well-characterized model systems. VHL identified species-specific metabolic and cofactor needs across each cell type, delivering targeted supplement designs.
Four persona-specific technical one-pagers with case studies, results, and platform architecture — ready to share with your team, CMC lead, or partners.
Tell us about your program. We offer substantial discounts for new modalities or applications.
Start a conversation →